Virtual Library

Start Your Search

Ulrike Setinek

Author of

  • +

    P2.13 - Targeted Therapy (Not CME Accredited Session) (ID 962)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.13-03 - Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients (ID 13703)

      16:45 - 18:00  |  Author(s): Ulrike Setinek

      • Abstract
      • Slides


      Patients with lung cancer, who show EML4-ALK translocation are routinely treated with ALK inhibitors (ALKi) as Alectinib, Ceritinib or Crizotinib, but develop resistance over time in the majority of cases. Brigatinib, a new next-generation ALKi, is FDA approved in crizotinib-refractory ALK-positive NSCLC. The role of Brigatinib after Ceritinib or Alectinib failure is unknown in clinical practice. We report about our experience with Brigatinib in EML4-ALK translocated NSCLC patients, who became resistant to Alectinib, Ceritinib or Crizotinib.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We treated 35 EML4-ALK translocated NSCLC patients with Brigatinib. Patient characteristics including sex, age, race, presence/ absence of brain metastases and smoking history of ALK+ NSCLC patients were collected. All data were obtained from Otto-Wagner hospital from August 2015 until April 2018.

      Before receiving Brigatinib, the patients were either only treated with Crizotinib (n = 15), with Crizotinib and then Ceritinib (n = 12), with Alectinib (n=1), with Crizotinib and then Alectinib (n=3), with Crizotinib, then Ceritinib and then Alectinib (n=1) or with Ceritinib and Alectinib (n=3).

      All patients were treated with daily dose of 180 mg oral Brigatinib after a 7- day lead- in at 90 mg.

      4c3880bb027f159e801041b1021e88e8 Result

      27 patients were women and 8 men. 3 patients were smokers ( 8,5%), 9 were former smokers ( 25,7 %) and 23 were never smokers (65,7%). 13 patients had initial brain metastases (31%). 34 of the treated patients are Caucasians and 1 is Asian. 3 of the 35 showed a complete response (9%), 25 a partial response (76%) and 5 a disease progression (15%), 2 were not evaluable. 7 of the 13 patients with brain metastases responded to Brigatinib (54%). The median PFS (progression free survival) was 7.5 months (range 1-21) and treatment of 21 patients is still ongoing. Of the 15 patients, who received only Crizotinib before Brigatinib, 2 patients were complete responders, 12 were partial responders and 1 had disease progression. Of the 12 patients, who received Crizotinib followed by Ceritinib, 1 patient had a complete response, 9 partial response and 2 disease progression. All other patients demonstrated a partial response except two, who had disease progression with Brigatinib following Ceritinib/ Alectinib treatment. Brigatinib was well tolerated overall.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Brigatinib was highly effective in these pretreated EML4-ALK translocated NSCLC patients in clinical practice.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.